In muscle cells, UCP1 enhances mitochondrial biogenesis and functions in skeletal muscle; targeting UCP1 pharmacologically (e.g., with β3-adrenergic agonists or cold exposure) is an area of interest for combating obesity and metabolic diseases in individuals who are unable to exercise. This evidence concerns the gene UCP1 and obesity due to melanocortin 4 receptor deficiency.